224 related articles for article (PubMed ID: 35507508)
21. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Dunkle LM; Kotloff KL; Gay CL; Áñez G; Adelglass JM; Barrat Hernández AQ; Harper WL; Duncanson DM; McArthur MA; Florescu DF; McClelland RS; Garcia-Fragoso V; Riesenberg RA; Musante DB; Fried DL; Safirstein BE; McKenzie M; Jeanfreau RJ; Kingsley JK; Henderson JA; Lane DC; Ruíz-Palacios GM; Corey L; Neuzil KM; Coombs RW; Greninger AL; Hutter J; Ake JA; Smith K; Woo W; Cho I; Glenn GM; Dubovsky F;
N Engl J Med; 2022 Feb; 386(6):531-543. PubMed ID: 34910859
[TBL] [Abstract][Full Text] [Related]
22. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.
Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Roshanzamir K; Bayatani B; Taheri A; Petrovsky N; Li L; Barati S
Clin Microbiol Infect; 2022 Sep; 28(9):1263-1271. PubMed ID: 35436611
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack FP; Thomas SJ; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Moreira ED; Zerbini C; Bailey R; Swanson KA; Roychoudhury S; Koury K; Li P; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
N Engl J Med; 2020 Dec; 383(27):2603-2615. PubMed ID: 33301246
[TBL] [Abstract][Full Text] [Related]
25. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.
Dubé C; Paris-Robidas S; Primakova I; Destexhe E; Ward BJ; Landry N; Trépanier S
Reprod Toxicol; 2022 Jan; 107():69-80. PubMed ID: 34838689
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
[TBL] [Abstract][Full Text] [Related]
27. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Al Kaabi N; Zhang Y; Xia S; Yang Y; Al Qahtani MM; Abdulrazzaq N; Al Nusair M; Hassany M; Jawad JS; Abdalla J; Hussein SE; Al Mazrouei SK; Al Karam M; Li X; Yang X; Wang W; Lai B; Chen W; Huang S; Wang Q; Yang T; Liu Y; Ma R; Hussain ZM; Khan T; Saifuddin Fasihuddin M; You W; Xie Z; Zhao Y; Jiang Z; Zhao G; Zhang Y; Mahmoud S; ElTantawy I; Xiao P; Koshy A; Zaher WA; Wang H; Duan K; Pan A; Yang X
JAMA; 2021 Jul; 326(1):35-45. PubMed ID: 34037666
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Lopez P; Bravo L; Buntinx E; Borja-Tabora C; Velasquez H; Rodriquez EJ; Rodriguez CA; Carlos J; Montellano MEB; Alberto ER; Salvani-Bautista M; Huang Y; Hu B; Li P; Han HH; Baccarini C; Smolenov I
Hum Vaccin Immunother; 2023 Dec; 19(1):2206359. PubMed ID: 37226504
[TBL] [Abstract][Full Text] [Related]
31. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Frenck RW; Klein NP; Kitchin N; Gurtman A; Absalon J; Lockhart S; Perez JL; Walter EB; Senders S; Bailey R; Swanson KA; Ma H; Xu X; Koury K; Kalina WV; Cooper D; Jennings T; Brandon DM; Thomas SJ; Türeci Ö; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
N Engl J Med; 2021 Jul; 385(3):239-250. PubMed ID: 34043894
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.
Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Kafi H; Fallah N; Ebrahimi A; Taheri A; Petrovsky N; Barati S
Clin Microbiol Infect; 2023 Feb; 29(2):215-220. PubMed ID: 36096430
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
El Sahly HM; Baden LR; Essink B; Doblecki-Lewis S; Martin JM; Anderson EJ; Campbell TB; Clark J; Jackson LA; Fichtenbaum CJ; Zervos M; Rankin B; Eder F; Feldman G; Kennelly C; Han-Conrad L; Levin M; Neuzil KM; Corey L; Gilbert P; Janes H; Follmann D; Marovich M; Polakowski L; Mascola JR; Ledgerwood JE; Graham BS; August A; Clouting H; Deng W; Han S; Leav B; Manzo D; Pajon R; Schödel F; Tomassini JE; Zhou H; Miller J;
N Engl J Med; 2021 Nov; 385(19):1774-1785. PubMed ID: 34551225
[TBL] [Abstract][Full Text] [Related]
35. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
37. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina M; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Health Technol Assess; 2010 Dec; 14(55):193-334. PubMed ID: 21208550
[TBL] [Abstract][Full Text] [Related]
38. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
Mostafavi E; Eybpoosh S; Karamouzian M; Khalili M; Haji-Maghsoudi S; Salehi-Vaziri M; Khamesipour A; Jalali T; Nakhaeizadeh M; Sharifi H; Mansoori Y; Keramat F; Ghodrati S; Javanian M; Doroud D; Omrani MD; Asadi H; Pouriayevali MH; Ghasemian R; Farshidi H; Pourahmad M; Ghasemzadeh I; Mounesan L; Darvishian M; Mirjalili MR; Toledo-Romani ME; Valenzuela-Silva C; Verez-Bencomo V; Gouya MM; Emadi-Koochak H; Haghdoost AA; Biglari A;
JAMA Netw Open; 2023 May; 6(5):e2310302. PubMed ID: 37133864
[TBL] [Abstract][Full Text] [Related]
40. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
